IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives $747.00 Average PT from Brokerages

IDEXX Laboratories, Inc. (NASDAQ:IDXX) has earned an average recommendation of “Moderate Buy” from the ten research firms that are covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $747.00.

IDXX has been the topic of a number of recent analyst reports. Barclays dropped their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Citigroup lifted their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. Finally, UBS Group increased their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th.

Hedge Funds Weigh In On IDEXX Laboratories

Institutional investors have recently modified their holdings of the company. SHP Wealth Management bought a new stake in IDEXX Laboratories during the fourth quarter worth approximately $26,000. Virtus Advisers LLC bought a new position in IDEXX Laboratories during the 3rd quarter valued at $26,000. J.Safra Asset Management Corp bought a new stake in shares of IDEXX Laboratories in the 2nd quarter worth $25,000. Elevation Wealth Partners LLC lifted its holdings in shares of IDEXX Laboratories by 188.2% in the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after buying an additional 32 shares during the period. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its stake in IDEXX Laboratories by 58.8% during the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 20 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 2.9%

IDEXX Laboratories stock opened at $545.86 on Friday. IDEXX Laboratories has a 12 month low of $518.55 and a 12 month high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The business has a 50 day simple moving average of $560.09 and a 200-day simple moving average of $577.02. The stock has a market capitalization of $43.00 billion, a PE ratio of 38.39, a price-to-earnings-growth ratio of 3.00 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. The company had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the firm earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, analysts anticipate that IDEXX Laboratories will post 14.81 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.